Prophylactic magnesium to decrease the arrhythmogenic potential of class III antiarrhythmic agents in a rabbit model

Pharmacotherapy

Volumn 19, Issue 5, 1999, Pages 635-640

  White, C Michael ^a,d,e   Xie, Jianlin ^a,b,d   Chow, Moses S S ^d   Kluger, Jeffrey ^b,c,d  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

^c UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; CLOFILIUM; MAGNESIUM SULFATE; METHOXAMINE;

ACTION POTENTIAL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ELECTROCARDIOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PROPHYLAXIS; QT INTERVAL; RABBIT; TORSADE DES POINTES;

EID: 0032900616     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.8.635.31528     Document Type: Article

References (34)

1. Volgman AS, Carberry PA, Stambler B, et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol 1998;31:1414-19.
2. Goodman JS, Peter CT. Proarrhythmia: rimum non nocere. In: Mandel WJ, ed. Cardiac arrhythmias: their mechanisms, diagnosis, and management, 3rd ed. Philadelphia: JB Lippincott, 1995:173-91.
3. Napolitano C, Priori SG, Schwartz PJ. Torsade de pointes: mechanisms and management. Drugs 1994;47:51-65.
4. Tzoni D, Banai S, Schuger C. Treatment of torsades de pointes with magnesium sulfate. Circulation 1988;77:292-7.
5. Baai S, Tzivoni D. Drug therapy for torsades de pointes. J Cardiovasc Electrophysiol 1983;4:206-10.
6. Keren A, Tzivoni D. Magnesium therapy in ventricular arrhythmias. PACE 1990;13:937-45.
7. Carlsson L, Drews L, Duker G, Schiller-Linhardt G. Attenuation of proarrhythmia related to delayed repolarization by low dose lidocaine in the anesthetized rabbit. J Pharmacol Exp Ther 1993;267:1076-80.
8. Buchanan LV, Kabell G, Brunden MN, Gibson JK. Comparative assessment of ibutilide, d-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia. J Cardiovasc Pharmacol 1993;220:540-9
9. Kr blockade: implications for the antifibrillatory efficacy of potassium channel blocking agents. J Am Coll Cardiol 1995;25:1609-14.
10. Whalley DW, Wendt DJ, Grant AO. Basic concepts in cellular cardiac electrophysiology. II. Block of ion channels by antiarrhythmic drugs. PACE 1995;18(part 1):1686-1704.
11. Roden DM. Ionic mechanisms for prolongation of refractoriness and their proarrhythmic and antiarrhythmic correlates. Am J Cardiol 1996;78(suppl 4A):12-16.
12. Kr: implications for torsades de pointes and reverse use dependence. Circulation 1996;93:407-11.
13. Balser JR, Bennett PB, Honghem LM, Roden DM. Suppression of time dependent outward current in guinea pig ventricular myocytes: actions of quinidine and amiodarone. Circ Res 1991;69:519-29.
14. Arena JP, Kass RS. Block of heart potassium channels by clofilium and its tertiary analogs: relationship between drug structure and type of channel blocked. Molec Pharmacol 1988;34:60-6.
15. Lee KS. Ibutilide, a new compound with potent class III antiarrhythmic activity, activates a slow inward Na current in guinea pig ventricular cells. J Pharmacol Exp Ther 1992;262:99-108.
16. Daleau P, Lessard E, Groleau MF, Turgeon J. Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes. Circulation 1995;91:3010-16.
17. Roden DM. Antiarrhythmic drugs. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's pharmacologic basis of therapeutics, 9th ed. New York: McGraw-Hill, 1996:839-74.
18. White RE, Hartzell HC. Magnesium ions in cardiac function: regulator of ion channels and second messengers. Biochem Pharmacol 1989;38:859-67.
19. Millane TA, Ward DE, Camm AJ. Is hypomagnesemia arrhythmogenic? Clin Cardiol 1992;15:103-8.
20. Cranefield PF, Aronson RS. Torsade de pointes and early afterdepolarizations. Cardiovasc Drugs Ther 1991;5:531-8
21. Sato T, Hirao K, Hiejma K. The relationship between early after-depolarizations and the occurrence of torsade de pointes. Jpn Circ J 1993;57:543-52.
22. Bailie DS, Inoue H, Kaseda S, Ben-David J, Zipes DP. Magnesium suppression of early after-depolarizations and ventricular tachyarrhythmias induced by cesium in dogs. Circulation 1988;77:1395-1402.
23. Takahashi N, Ito M, Ishida S, Fulino T, Saikawa T, Arito M. Effects of vagal stimulation on cesium-induced early afterdepolarizations and ventricular arrhythmias in rabbits. Circulation 1992;86:1987-92.
24. Kaseda S, Gilmour RF, Zipes DP. Depressant effect of magnesium on early after-depolarizations and triggered activity induced by cesium, quinidine, and 4-aminopyridine in canine cardiac purkinje fibers. Am Heart J 1989;118:458-66.
25. Weissenburger J, Davy JM, Chezalviel F. Experimental models of torsades de pointes. Fundam Clin Pharmacol 1993;7:29-38.
26. Carlsson L, Almgren O, Duker G. QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: etiology and interventions. J Cardiovasc Pharmacol 1990;16:276-85.
27. Lewis RV, Tregaskis B, McLay J, Service E, McDevitt DG. Oral magnesium reduces ventricular ectopy in digitalised patients with chronic atrial fibrillation. Eur J Clin Pharmacol 1990;38:107-10.
28. Critelli G, Reale A. Magnesium and cardiac arrhythmias: reappraisal of an old substance. Cardiologia 1990;35:39-42.
29. Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized controlled trials. Circulation 1990;82:1106-16.
30. Zabel M, Hohnloser SH, Behrens S, Woosley RL, Franz MR. Differential effects of d-sotalol, quinidine, and amiodarone on dispersion of ventricular repolarization in the isolated rabbit heart. J Cardiovasc Electrophysiol 1997;8:1239-45.
31. Waldo AL, Camm AJ, de Ruyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996;348:7-12.
32. Cropp JS, Antal EG, Talbert RL. Ibutilide: a new class III antiarrhythmic agent. Pharmacotherapy 1997;17:1-9.
33. Mason JW, for the ESVEM Investigators. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N EnglJ Med 1993;329:452-8.
34. O'Callaghan PA, McGovern BA. Evolving role of sotalol in the management of ventricular tachyarrhythmias. Am J Cardiol 1996;78(suppl 4A):54-60.